25.11.2017 00:15:00
|
How the CFO of a $12 Billion Biotech Startup Eliminated the Frustrations of Lab Procurement through Procurify
VANCOUVER, Nov. 24, 2017 /CNW/ - Samumed is a leader in biotech research for regenerative medicine - that also happens to be the most valued biotech startup in the world.
As Samumed added more people to its team, and embarked on more ambitious and expensive projects, the CFO of Samumed, Cevdet Samikoglu, felt the need to root out any operational inefficiencies and problems that could impede its growth.
Samumed turned to Procurify, a purchasing software solution, to streamline its lab operations and procurement process.
"Given our rapid growth, it would have been impressive for us just to maintain our previous procurement timeline. Instead, Procurify has cut that time in half, which is truly outstanding." - Cevdet Samikoglu, CFO, Samumed
Biotech insiders will attest to the importance of streamlining lab operations. When high growth companies such as Samumed scale quickly, they need to keep up with the increase of personnel and purchases. What the most successful biotech companies in the world do is adopt systems to manage company growth and control spend.
"Procurify hasn't just freed up time and created efficiency — it has allowed our accountants to file their reports with the confidence that all their data is up-to-date and accurate."
About Procurify
Procurify is reinventing the way companies spend, track and report.
For companies looking to make their purchasing process manageable, Procurify is a software solution that offers convenience and accessibility. Company purchases do not have to be overwhelming or complex, Procurify offers a smarter way to manage spend for hundreds of companies around the world.
SOURCE Procurify Technologies Inc.
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu PennyMac Mortgage Investment Trustmehr Nachrichten
21.10.24 |
Ausblick: PennyMac Mortgage Investment Trust präsentiert Quartalsergebnisse (finanzen.net) | |
22.07.24 |
Ausblick: PennyMac Mortgage Investment Trust legt die Bilanz zum abgelaufenen Quartal vor (finanzen.net) |
Analysen zu PennyMac Mortgage Investment Trustmehr Analysen
Aktien in diesem Artikel
Novo Nordisk (spons. ADRs) | 101,00 | 4,99% | |
PennyMac Mortgage Investment Trust | 12,80 | 0,79% |